Related Experiment Video
Updated: Jul 27, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Chimeric antigen receptor therapy for hepatocellular carcinoma
Lorenz Kocheise1, Mohamed-Reda Benmebarek1, Mitchell Ho2
1Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Adapting the success of chimeric antigen receptor T cell therapy from hematologic malignancies to solid tumors has become a major focus of ongoing research activities. However, the unique challenges posed by solid tumors, such as limited immune cell infiltration, reduced T cell persistence, and antigen loss, have led to only limited success in early clinical trials. Recently, combinatorial strategies incorporating next-generation armored CAR T cells along with various alternative immune cell types have rekindled optimism in the field. Hepatocellular carcinoma represents a distinct entity due to the unique characteristics of the liver microenvironment, including the influence of lipid metabolism, bile acids, and microbial compounds from the gut-liver axis. Furthermore, HCC is characterized by a variety of tumor-specific and tumor-associated antigens, enabling targeted approaches with minimal risk of on-target/off-tumor effects. The unique complexity of HCC, along with the underlying liver diseases that give rise to these tumors, presents both challenges and opportunities for cellular therapies. In this review, we examine the current landscape of CAR T cell therapy for HCC, highlighting recent clinical and preclinical developments. Furthermore, we discuss why HCC may be especially well-suited for tailored CAR-based strategies, given the liver's specific anatomical and immunological properties.
Insights
Chimeric antigen receptor T cell (CAR T) therapy shows promise for hepatocellular carcinoma (HCC). The liver microenvironment presents unique challenges and opportunities for CAR T cell efficacy in treating this liver cancer.
Area of Science:
- Immunology
- Oncology
- Cellular Therapy
Background:
- Adapting chimeric antigen receptor T cell (CAR T) therapy from blood cancers to solid tumors is challenging due to factors like poor T cell infiltration and antigen loss.
- Hepatocellular carcinoma (HCC) has a unique liver microenvironment influenced by metabolism and the gut-liver axis, presenting specific hurdles and potential for cellular therapies.
Purpose of the Study:
- To review the current status of CAR T cell therapy for hepatocellular carcinoma (HCC).
- To explore the potential of HCC as a suitable target for tailored CAR T cell strategies, considering the liver's unique properties.
Main Methods:
- Review of recent clinical and preclinical developments in CAR T cell therapy for HCC.
- Analysis of the liver microenvironment's characteristics and their impact on cellular therapy efficacy.
- Examination of HCC-specific antigens for targeted therapeutic approaches.
Main Results:
- Solid tumors, including HCC, present significant challenges for CAR T cell therapy, limiting early clinical success.
- Combinatorial strategies and next-generation CAR T cells are improving outcomes.
- HCC's specific antigens and liver microenvironment offer unique opportunities for targeted CAR T cell therapies.
Conclusions:
- Despite challenges, HCC may be particularly well-suited for advanced CAR T cell strategies due to its distinct immunological and anatomical features.
- Tailored CAR T cell approaches hold significant promise for improving HCC treatment outcomes.
- Further research into the interplay between CAR T cells and the liver microenvironment is crucial.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy